News with Multimedia
-
Renesas Introduces New Entry-Level RA0 MCU Series with Best-in-Class Power Consumption
04/09/2024 - 08:00 PM
-
Options and Magtia Empower Trading Firms with Next Generation Symbology Solution
04/09/2024 - 06:31 PM
-
Prolia ® 及 Xgeva ® 的第 3 階段比較臨床試驗 (denosumab) 生物相似藥 HLX14 達到主要臨床試驗終點
04/09/2024 - 05:48 PM
-
NEDO wählt IHI Technology Development Initiative für grünes Innovationsfondsprojekt zur Beschleunigung der Elektrifizierung von Flugzeugen
04/09/2024 - 05:31 PM
-
La NEDO choisit l’initiative de développement technologique d’IHI pour un projet du fonds d’innovation écologique visant à accélérer les efforts d’électrification des aéronefs
04/09/2024 - 05:31 PM
-
Faraday Future Continues Progress in the Middle East Market with Establishment of a Middle East Sales Entity
04/09/2024 - 05:09 PM
-
香港貿發局禮品展及印刷包裝展四月舉行
04/09/2024 - 04:55 PM
-
Hong Kong Gifts & PrintPack Fairs Open in April
04/09/2024 - 04:54 PM
-
NEDO Chooses IHI Technology Development Initiative for Green Innovation Fund Project to Accelerate Aircraft Electrification Efforts
04/09/2024 - 12:49 PM
-
The AI-Based Smart Contract Audit Firm "Bunzz Audit" Has Officially Launched
04/09/2024 - 12:00 PM
-
Asia’s Thriving Cruise Destinations Set to Enrich Regional Cruise Experiences
04/09/2024 - 06:43 AM
-
OpenX Promotes Mitchell Greenway to Managing Director, APAC
04/09/2024 - 06:05 AM
-
Estudo clínico comparativo de fase 3 do candidato a biossimilar do Prolia ® e do Xgeva ® (denosumabe), o HLX14, alcança desfechos primários
04/09/2024 - 02:32 AM
-
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios
04/09/2024 - 02:32 AM
-
L'essai clinique comparatif de phase 3 du candidat biosimilaire de Prolia ® et de Xgeva ® (denosumab) HLX14 remplit les critères d'évaluation primaires
04/09/2024 - 02:31 AM